Editing Ranbaxy Laboratories (section)

=== Acquisition by Daiichi Sankyo ===

In June 2008, [[Daiichi Sankyo]] acquired a 34.8% stake in Ranbaxy from the family of CEO and Managing Director [[Malvinder Mohan Singh]] for [[Indian Rupee|{{INR}}]] 10,000 [[crore]] (US$2.4 billion) at {{INR}}737 per share.<ref name="Wharton20080612">{{cite web |last1=Staff |title=The Ranbaxy-Daiichi Deal: Good Medicine, or a Harbinger of Future Ills? - Knowledge@Wharton |url=http://knowledge.wharton.upenn.edu/article/the-ranbaxy-daiichi-deal-good-medicine-or-a-harbinger-of-future-ills/ |website=Knowledge@Wharton |publisher=[[Wharton School]] |access-date=2018-08-11 |date=12 June 2008}}</ref><ref>{{Cite web|url=http://www.pharmaexhibition.com/Exhibit/Ranbaxy-Laboratories-Limited/India/Home|archive-url=https://archive.today/20130131175140/http://www.pharmaexhibition.com/Exhibit/Ranbaxy-Laboratories-Limited/India/Home|url-status=dead|title=Ranbaxy joined "Online Pharma Exhibition"|archive-date=31 January 2013}}</ref>

In November 2008, [[Daiichi-Sankyo]] completed the takeover of the company from the founding Singh family in a deal worth $4.6 billion{{Dubious|reason=This doesn't agree with the more complicated deal described (in future tense) in the Bloomberg article. Fix. |date=August 2018}}<ref>[https://web.archive.org/web/20110612111139/http://business.timesonline.co.uk/tol/business/industry_sectors/health/article4115884.ece TimesOnlineUK – Business – Takeover of Ranbaxy]</ref> by acquiring a 63.92% stake in Ranbaxy. Ranbaxy's [[Malvinder Mohan Singh|Malvinder Singh]] remained as CEO after the transaction.<ref>Matsuyama, Kanoko. (11 June 2008) [https://www.bloomberg.com/apps/news?pid=newsarchive&sid=aMiwVweIVD60 Daiichi to Take Control of Ranbaxy for $4.6 Billion – 11 June 2008]. Bloomberg.</ref>
The addition of Ranbaxy Laboratories extended Daiichi-Sankyo's operations, with the combined company worth about US$30 billion.<ref>{{Cite news|title = Japanese drugmaker Daiichi Sankyo gobbles Ranbaxy Laboratories for $4.6 billion|date = 12 June 2008|archive-date = 16 November 2009|url = http://www.ibtimes.co.in/articles/20080612/ranbaxy-laboratories-daiichi-sankyo-generic-drug-pharmaceutical-takeover-acquisition-malvinder-singh.htm|archive-url = https://web.archive.org/web/20091116192726/http://www.ibtimes.co.in/articles/20080612/ranbaxy-laboratories-daiichi-sankyo-generic-drug-pharmaceutical-takeover-acquisition-malvinder-singh.htm|first = Surojit|last = Chatterjee|work = [[International Business Times]]|location = New York}}</ref>

In 2009, it was reported that former [[Novartis]] Senior Vice-President Yugal Sikri would lead the Indian operations of Ranbaxy Laboratories.<ref>{{cite web |url=http://www.ranbaxy.com/common/ContactRegion.aspx?id=59&flag= |title=Ranbaxy Laboratories Limited > Contact Us > Worldwide Operations > India |publisher=Ranbaxy.com |url-status=dead |archive-url=https://web.archive.org/web/20120404065634/http://www.ranbaxy.com/common/ContactRegion.aspx?id=59&flag= |archive-date=4 April 2012}}</ref><ref>{{cite web|author=ET Bureau |url=http://articles.economictimes.indiatimes.com/2009-09-11/news/27658542_1_japanese-company-daiichi-sankyo-ranbaxy-laboratories-yugal-sikri |archive-url=https://web.archive.org/web/20130906115812/http://articles.economictimes.indiatimes.com/2009-09-11/news/27658542_1_japanese-company-daiichi-sankyo-ranbaxy-laboratories-yugal-sikri |url-status=dead |archive-date=6 September 2013 |title=Yugal Sikri to be New India CEO of Ranbaxy |work=The Economic Times |date=11 September 2009}}</ref>

In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award. 

In 2012, 2013, and 2014 Brand Trust Reports, Ranbaxy was ranked 161st, 225th, and 184th respectively among India's most trusted brands.<ref>{{Cite web|url =http://www.trustadvisory.info/allindia_2014.html|title =India's Most Trusted Brands 2014|publisher =Trust Research Advisory|url-status =dead|archive-url =https://web.archive.org/web/20150502221904/http://www.trustadvisory.info/allindia_2014.html|archive-date =2 May 2015}}</ref>